Gilead Sciences, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$119Mgeneral payments (2019-2025)
$1.8Mresearch payments (2019-2025)
90,323clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Epclusa $8.5M associated (2023-2025)
- Trodelvy $7.8M associated (2023-2025)
- Biktarvy $7.3M associated (2023-2025)
- Descovy $4.1M associated (2023-2025)
- Livdelzi $3.6M associated (2023-2025)
- Vemlidy $2.5M associated (2023-2025)
- Yeztugo $2.4M associated (2023-2025)
- Veklury $1.7M associated (2023-2025)
- Sunlenca $483K associated (2023-2025)
- Yescarta $336K associated (2023-2025)
- Ambisome $55K associated (2023-2025)
- Tecartus $20K associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Sandra Horning | Stanford, CA | Hematology & Oncology | $2,038,903.65 |
| Richard Whitley | Birmingham, AL | Pediatric Infectious Diseases | $1,076,919.93 |
| Ted Love | Hillsborough, CA | Cardiovascular Disease | $858,229.67 |
| Zobair Younossi | Falls Church, VA | Surgery | $610,090.57 |
| Robert Gish | Folsom, CA | Hepatology | $574,200.83 |
| Anthony Martinez | Buffalo, NY | Internal Medicine | $548,559.86 |
| Douglas Dieterich | New York, NY | Hepatology | $540,026.77 |
| David Wohl | Chapel Hill, NC | Infectious Disease | $480,860.08 |
| Jihad Slim | Newark, NJ | Infectious Disease | $465,193.82 |
| Steven Flamm | Chicago, IL | Gastroenterology (Internal Medicine) | $459,864.02 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.